29-06-2025
William Blair Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
William Blair analyst Matt Phipps reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday. The company's shares closed last Friday at $441.30.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Phipps covers the Healthcare sector, focusing on stocks such as Cullinan Management, Genmab, and Bristol-Myers Squibb. According to TipRanks, Phipps has an average return of -9.1% and a 36.43% success rate on recommended stocks.
In addition to William Blair, Vertex Pharmaceuticals also received a Buy from H.C. Wainwright's Andrew Fein in a report issued on June 23. However, on June 27, RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
